Attention investors who purchased shares of QIAGEN N.V. before March 3, 2020:
Rigrodsky & Long is investigating potential claims against the board of directors of QIAGEN N.V. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Thermo Fisher Scientific, Inc.
Rigrodsky & Long, P.A. announces that it is investigating QIAGEN N.V. (“QIAGEN") (NYSE: QGEN) regarding possible breaches of fiduciary duties and other violations of law related to QIAGEN's agreement to be acquired by Thermo Fisher Scientific, Inc. (“Thermo Fisher”) (NYSE: TMO). Under the terms of the agreement, shareholders of QIAGEN will receive €39.00 in cash per share.
If you would like to discuss this investigation and your rights cost and obligation free, please contact Seth D. Rigrodsky or Gina M. Serra toll free at (888) 969-4242 or by e-mail at email@example.com.
Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.
Attorney advertising. Prior results do not guarantee a similar outcome.